Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma—a real-world multicenter retrospective cohort study-Reference-Cited by-同舟云学术

Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma—a real-world multicenter retrospective cohort study

Published:2023-06-19 Issue:8 Volume:102 Page:2127-2136
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Berger Tamar^ORCID,Shochat Tzippy,Aumann Shlomzion,Nachmias Boaz,Goldschmidt Neta,Horesh Nurit,Harel Reut,Aviv Ariel,Shmerts Ella,Abadi Uri,Shimony Shai,Raanani Pia,Gafter‑Gvili Anat,Gurion Ronit

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-023-05306-2.pdf

Reference28 articles.

1. Teras LR, DeSantis CE, Cerhan JR et al (2016) 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 66:443–459. https://doi.org/10.3322/caac.21357

2. Dotan E, Aggarwal C, Smith MR (2010) Impact of rituximab (rituxan) on the treatment of B-cell non-Hodgkin’s lymphoma. P T 35:148–157

3. Schulz H, Bohlius JF, Trelle S et al (2007) Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 99:706–714. https://doi.org/10.1093/jnci/djk152

4. Marcus R, Davies A, Ando K et al (2017) Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 377:1331–1344. https://doi.org/10.1056/NEJMoa1614598

5. Townsend W, Buske C, Cartron G et al (2020) Comparison of efficacy and safety with obinutuzumab plus chemotherapy versus rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: updated results from the phase III Gallium Study. JCO 38:8023–8023. https://doi.org/10.1200/JCO.2020.38.15_suppl.8023

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An international multicenter study comparing COVID‐19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab;Cancer Medicine;2024-02